Category: Anaemic Hypoxia

DUBLIN–(BUSINESS WIRE[1])–The “Iron Deficiency Anemia Pipeline Research Monitor, 2020 – Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook”[2] report has been added to ResearchAndMarkets.com’s offering. PIPELINE HIGHLIGHTS Iron Deficiency Anemia is one of the widely researched conditions during 2020 with 13 companies actively focusing on realizing pipeline’s potential. Development of Iron Deficiency Anemia medicines is identified as integral...

MORRISTOWN, N.J., Feb. 10, 2020 /PRNewswire/ — Pharmacosmos Therapeutics Inc. announced today that it has been established as a newly formed specialty pharmaceutical company dedicated to commercializing Monoferric® for Iron Deficiency Anemia (IDA) patients in the US. The new company is a subsidiary of the Pharmacosmos Group, a profitable, fast-growing specialty pharmaceutical company headquartered in Denmark. Monoferric® is an intravenous...

MANHASSET, N.Y.–(BUSINESS WIRE[1])–Nearly 1.6 billion people worldwide suffer from anemia, and for the first time new research points to how resistance emerges to the drug dexamethasone used to treat the devastating inherited form of anemia known as Diamond Blackfan anemia (DBA). The Feinstein Institutes for Medical Research[2] professor and expert in disorders of the red cell Lionel Blanc, PhD,[3] published...

Issued: London, UK GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a Japanese New Drug Application (JNDA) to the Ministry of Health, Labour and Welfare seeking marketing approval for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with renal anaemia due to chronic kidney disease (CKD). Dr Hal Barron, Chief Scientific Officer and...